Global Smart Insulin Pens Industry Poised For Spectacular 8.3% Cagr Surge, Anticipated To Hit Us$ 8,750.7 Million By 2033

The Global Smart Insulin Pens Industry is projected to reach a value of US$ 3,927.3 million in 2023, with an anticipated increase to US$ 8,750.7 million by 2033. The adoption of smart insulin pens is poised for substantial growth, with a projected compound annual growth rate (CAGR) of 8.3% during the forecast period.

In light of the escalating global diabetic population, smart insulin pumps are gaining prominence. Healthcare stakeholders and patients are exploring innovative therapeutic strategies to address this growing concern. Smart insulin pumps are expected to emerge as a suitable solution in response to this demand. The ever-increasing demands of hospital workflows are driving investments in cloud-based insulin level monitoring methods, thereby expanding the horizons for growth.

Download a Sample of this Report Now!
https://www.futuremarketinsights.com/reports/sample/rep-gb-1827

Manufacturers are thus capitalizing on these trends to launch fresh and inventive product lines, allowing them to gain a firm foothold in the market. Medtronic, for example, will debut its InPenTM smart insulin device with real-time GuardianTM Connect CGM Data in November 2020, making it the first smart insulin pen for diabetics who require many daily injections. BioCorp and Roche Diabetes Care just launched the Mallya smart insulin pen device in France in April 2021.

Key Takeaways from FMI’s Global Smart Insulin Pens Industry Report

• Bluetooth-enabled Smart Insulin Pens will account for more than half of the revenue share by 2031.
• According to indications, type 2 diabetes therapy will account for the majority of smart insulin pen deployment.
• Smart Insulin Pens were primarily distributed through retail pharmacies, with e-commerce sales fast increasing.
• The United States will see credible growth as the approval rate for new diabetes treatment devices rises.
• Growing acceptance of needle-free insulin injections in the United Kingdom
• In the long run, Germany and France will see increasing collaboration between key manufacturers.
• A high concentration of regional manufacturers will drive growth in India and China.

Global Smart Insulin Pens Industry – Key questions answered in the report

What trends are in store for the Global Smart Insulin Pens Industry growth?

According to FMI, the Global Smart Insulin Pens Industry is expected to reach multi-billion dollar valuations in both the short and long run, owing to an increase in the global diabetes population pool and the resulting increase in hospital workload. Bluetooth-enabled Smart Insulin Pens are predicted to stay in high demand.

Which is the most promising Global Smart Insulin Pens Industry?

According to FMI’s estimate, demand for Smart Insulin Pens is projected to continue high in the US market, owing to the government’s ongoing efforts to eradicate the diabetes epidemic through major advertising campaigns. Furthermore, with the presence of multiple regional-level producers, India and China are likely to emerge as the main markets in the Asia-Pacific region.

Competitive Landscape

significant insulin pen manufacturers are efficiently using significant expansion tactics, such as new product releases and R&D, collaboration with current manufacturers, and outright/partial purchase of important market participants. The incorporation of virtual technological breakthroughs to improve diabetes care is being prioritized.

Novo Nordisk and the University of Toronto signed a CAD 40 million investment agreement in February 2021 to establish the Novo Nordisk Network for Healthy Populations. This network will concentrate on novel methods of diabetes management and chronic disease prevention. This will most likely aid in the creation of Smart Insulin Pens.

Companies are also focusing on providing advanced software platforms, such as Digital Medics’ DiabetesPlus DataSync Software. This platform enables users to download insulin and glucose data directly from the device. Key features include downloading insulin data from the insulin pen, glucose levels from the glucose meter, and synchronization of data on the Cloud for use with mobile devices.

Key Players

• Digital Medics Pty Ltd.
• Emperra GmbH e-Health Technologies
• Companion Medical Inc.
• Sanofi Aventis LLC
• Novo Nordisk A/S
• Eli Lily and Company
• Companion Medical
• Diabnext
• Jiangsu Delfu Medical Device Co. Ltd.
• DIAMESCO Co Ltd.
• Patients Pending Ltd (Bigfoot Biomedical Inc.)
• BERLIN-CHEMIE

Global Smart Insulin Pens Industry – Key Segments Covered

Indication

• Diabetes Type I
• Diabetes Type II

Connectivity

• Bluetooth Connected
• USB Connected

Distribution Channel

• Clinics & Ambulatory Surgical Centers
• E-Commerce
• Retail Pharmacies